Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Respiratory, thoracic and mediastinal disorders – page 28

  • 1 276 clinical trials
  • 446 recruiting
  • 379 conditions
  • 28 countries

Conditions in this area

379 conditions with trials, the busiest first

Non-small cell lung cancer327Asthma88Non-small cell lung cancer metastatic82Chronic obstructive pulmonary disease60Non-small cell lung cancer stage IV57COVID-1939Pulmonary arterial hypertension38Non-small cell lung cancer stage III37Idiopathic pulmonary fibrosis34Pneumonia32Small cell lung cancer32Non-small cell lung cancer stage IIIB31Small cell lung cancer extensive stage31Influenza28Interstitial lung disease28Lung neoplasm malignant28Cystic fibrosis24Conjunctivitis allergic23Pulmonary hypertension23Chronic rhinosinusitis with nasal polyps21Respiratory syncytial virus infection20Rhinitis allergic20Post-acute COVID-19 syndrome19Ovarian cancer18+355

Clinical trials in Respiratory, thoracic and mediastinal disorders

1 276 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 276 clinical trials

Lung transplant+1

Recruiting

Study on the Safety of Allogeneic Mesenchymal Stromal Cells for Patients with Chronic Lung Transplant Rejection

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Allogeneic Bone Marrow-Derived Mesenchymal Adult Stromal Cells, Ex-Vivo Expanded
  • Sponsor:Fundacion Para La Investigacion Biomedica Del Hospital Universitario Puerta De Hierro Majadahonda

Non-small cell lung cancer

Recruiting

Study of Pembrolizumab and V940 for Treating Non-Small Cell Lung Cancer in Patients with Resectable Stage II to IIIB (N2) Not Achieving Complete Response

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Acute respiratory distress syndrome

Recruiting

Study on the Safety and Benefits of Recombinant Human Plasma Gelsolin for Patients with Moderate-to-Severe Acute Respiratory Distress Syndrome (ARDS)

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Human Plasma Gelsolin, Recombinant
  • Sponsor:Bioaegis Therapeutics Inc.

Keratinising squamous cell carcinoma of nasopharynx+2

Recruiting

Study of nivolumab treatment for patients with nasopharyngeal cancer who did not respond to or worsened after platinum chemotherapy

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie-Panstwowy Instytut Badawczy

Pulmonary sarcoidosis

Recruiting

Study on Methotrexate and Prednisone for Treating Lung Sarcoidosis in Patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Methotrexate
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Non-small cell lung cancer

Recruiting

Study on the Effectiveness of Cemiplimab and Drug Combination for Patients with Oligometastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Institut Gustave Roussy

Obstructive airways disorder

Recruiting

Study on the Effects of Umeclidinium and Vilanterol in Patients with COPD and Heart Failure

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Salbutamol Sulfate
  • Sponsor:Hospital General Universitario Gregorio Maranon

Non-small cell lung cancer

Recruiting

Study on Modified Osimertinib Dosing with Cobicistat for Advanced Non-Small Cell Lung Cancer in Patients with EGFR Mutation

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Cobicistat
  • Sponsor:Academisch Ziekenhuis Maastricht

Non-small cell lung cancer

Recruiting

Study Comparing Standard and Adjusted Doses of Alectinib for Patients with ALK Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Alectinib
  • Sponsor:Universitair Medisch Centrum Groningen

Pneumonia

Recruiting

Study on the Effects of Oseltamivir and Drug Combination for Patients with Pneumonia

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Baloxavir Marboxil
  • Sponsor:University Of Oxford

Pulmonary arterial hypertension

Recruiting

Study on the Safety and Tolerability of Treprostinil Sodium for Children with Pulmonary Arterial Hypertension

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Treprostinil Sodium
  • Sponsor:Aop Orphan Pharmaceuticals GmbH

Endometrial cancer+3

Recruiting

Study on the Safety and Effects of Farletuzumab Ecteribulin for Patients with Ovarian, Breast, Endometrial, and Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:Eisai Limited

Substances studied in this area

The therapies tested most often in Respiratory, thoracic and mediastinal disorders trials.

Carboplatin169 clinical trialsPembrolizumab145 clinical trialsCisplatin128 clinical trialsPemetrexed108 clinical trialsPaclitaxel80 clinical trialsDurvalumab71 clinical trialsAtezolizumab50 clinical trialsNivolumab49 clinical trialsSodium Chloride49 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.